Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva’s new plant no longer idle

Executive Summary

Teva's new Jerusalem plant passed FDA inspection last month and is now operating, the generic firm announces during an analyst call Feb. 13. The plant was scheduled to be fully operational in early 2006 (1"The Pink Sheet" Aug. 14, 2006, p. 6). CEO Israel Makov says the plant started with a capacity of four billion tablets a year, with a goal to double that by year end...

You may also be interested in...



Teva’s Generic Zoloft Launch, And New Jerusalem Plant, Remain Idle

Teva's supply chain challenges appear to have caught up with the company in the form of further delays of its launch of Zoloft generics

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048062

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel